MicroStrategy (NASDAQ:MSTR) reported quarterly losses of $(20.51) per share which missed the analyst consensus estimate of $(0.13) by 15676.92 percent. This is a 143.88 percent decrease over losses of $(8.41) per share from the same period last year. The company reported quarterly sales of $132.55 million which beat the analyst consensus estimate of $131.33 million by 0.93 percent. This is a 1.46 percent decrease over sales of $134.51 million the same period last year.
What’s Going On With Chemomab Therapeutics Stock Today
Chemomab Therapeutics Ltd (NASDAQ: CMMB) reported topline results from secondary Phase 2a liver fibrosis trial analyses assessing CM-101 in patients with
